Solopharm, one of the leading pharmaceutical manufacturers in Russia, has launched a new, modern plant for the production of soft dosage forms. This significant project strengthens the company's market position and contributes to increasing the production volume of high-quality gels, ointments, and creams.
The new plant is equipped with a single production line, ensuring a full production cycle — from the synthesis of active pharmaceutical ingredients (APIs) to the release of finished soft dosage forms. This setup allows the company to significantly improve operational efficiency and guarantee high product quality. The plant will be capable of producing up to 1.5 million packages per year, meeting market demand.
The first product already launched on the line is the enterosorbent Solosorb. The company also expects registration certificates in areas such as gastroenterology, therapy, and dermatology.
The design of the production facilities is based on the modular Matrix Wall production system. The total area is 2,240 m², with 1,250 m² allocated to clean and classified rooms. This meets modern requirements for organizing production spaces and minimizing the risk of product contamination.
The presence of its own purification facilities, including a wastewater neutralization section, allows the company not only to comply with environmental regulations but also to maintain a high level of safety at all stages of production.
The ventilation system at the new site ensures that air preparation meets international GMP (Good Manufacturing Practices) standards, providing Class D cleanliness in the rooms, which is crucial for the production of medical products. Thus, Solopharm confirms its commitment to maintaining high quality and safety standards.
The opening of the new plant is a significant milestone for Solopharm, contributing to the development of domestic medicine. Improvements in technological processes, along with the application of modern quality management standards, will open new horizons for the production of effective and safe medications.
Solopharm continues to innovate, and the new plant will be a key element in the implementation of this strategy. 